Quantcast

Latest Quinazolines Stories

2014-10-29 12:27:14

Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo...

2014-10-22 08:30:21

DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States (US), China and Japan to the cancer drugs market research collection of its online library. The PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...

2014-10-15 23:01:37

New research report “Global Cancer Kinase Inhibitors Market & Pipeline Insight” elaborated by Kuick Research is now available at MarketPublishers.com. According to the study, the global kinase inhibitors market is poised to gain momentum through 2018. London, UK (PRWEB) October 15, 2014 The field of cancer is developing driven primarily by the ageing world population, soaring rates of smoking, and the growth in obesity across all geographies. This opens up a slew of nice...

2014-09-29 08:31:17

Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept. 29, 2014 /PRNewswire/ -- Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients. The primary objective of the study is to detect and...

2014-09-29 08:30:57

- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing the risk of disease progression by 18% RIDGEFIELD, Conn., Sept. 29, 2014 /PRNewswire/ -- Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung,...

2014-09-18 08:28:26

- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany, and RIDGEFIELD, Conn., Sept. 18, 2014 /PRNewswire/ -- Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel...

2014-08-18 16:28:13

WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed. "This trial demonstrates the power of CT screening to open new research windows on critical problems, such as recurrence, that have eluded...

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related